Vol 14, Supp. I (2020)
Editorial
Published online: 2020-12-30
Zastosowanie tabletek fentanylu podawanych drogą podjęzykową w leczeniu bólu przebijającego (epizodycznego) u chorych na nowotwory
DOI: 10.5603/PMPI.2020.0044
Abstract
Not available
References
- Løhre ET, Klepstad P, Bennett MI, et al. European Association for Palliative Care Research Network. From "Breakthrough" to "Episodic" Cancer Pain? A European Association for Palliative Care Research Network Expert Delphi Survey Toward a Common Terminology and Classification of Transient Cancer Pain Exacerbations. J Pain Symptom Manage. 2016; 51(6): 1013–1019.
- Davies AN, Dickman A, Reid C, et al. Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009; 13(4): 331–338.
- Narayana A, Katz N, Shillington AC, et al. National Breakthrough Pain Study: prevalence, characteristics, and associations with health outcomes. Pain. 2015; 156(2): 252–259.
- Pietrzyński Ł, Włodarska M, Danikiewicz M, et al. Ocena i leczenie bólu przebijającego u chorych na nowotwory. Palliative Medicine in Practice. 2018; 12(3): 156–164.
- Brząkała J, Leppert W. The role of rapid onset fentanyl products in the management of breakthrough pain in cancer patients. Pharmacol Rep. 2019; 71(3): 438–442.
- Løhre ET, Thronæs M, Klepstad P. Breakthrough cancer pain in 2020. Curr Opin Support Palliat Care. 2020; 14(2): 94–99.
- Webber K, Davies AN, Zeppetella G, et al. Development and validation of the breakthrough pain assessment tool (BAT) in cancer patients. J Pain Symptom Manage. 2014; 48(4): 619–631.
